

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Dr. Xueyu Chen
Name of drug and indication under review:	Regorafenib (Stivarga) for Hepatocellular Carcinoma

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 - □ Yes
 - 🖂 No

If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, HTA submission advice)	Program or Operating Funding (e.g., website)
Conference	Research/educational
attendance	grants
Royalties	Travel grants
Gifts	Sponsorship of Events

☐ Honoraria ☐ Other, please specify:

pCODR Clinician Conflict of Interest Declaration ©2018 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: _____ Name: _____

Signature:_____



Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:Janine DaviesName of drug and indication under review:Regorafenib for Hepatocellular Carcinoma

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 - 🖂 Yes
 - 🗆 No


If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)
Conference		Research/educational
attendance		grants
Royalties	\boxtimes	Travel grants
Gifts	\boxtimes	Sponsorship of Events

 \boxtimes Honoraria \square Other, please specify:

pCODR Clinician Conflict of Interest Declaration ©2018 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

no

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

no

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: 2017-10-16

Name: Janine M Davies

Signature:



Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Vincent Tam
-------------------------------	-------------

Name of drug and indication under review: ____regorafenib

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 - □ Yes
 - 🗆 No

If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, HTA submission advice)	Program or Operating Funding (e.g., website)
Conference	Research/educational
attendance	grants
Royalties	Travel grants
Gifts	Sponsorship of Events

- □ Gifts
 □ Sponsorship of Events
 □ Honoraria
 □ Other, please specify:
- pCODR Clinician Input on a Drug Review © 2018 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

NO

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

NO

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: October 13, Name: Vincent Tam 2017

Signature:



Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Jim Biagi

Name of drug and indication under review: Regorafenib for HCC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 □ Yes
 □ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - Advisory role (e.g., advisory boards, HTA submission advice)
 - □ Conference attendance
 - Royalties
 - □ Gifts
 - □ Honoraria
 - Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

 \square

 \square

Click here to enter text.



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

Section C: Affiliations, personal or commercial relationships

1

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below. No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: May 8 2017

Name: Jim Biagi

Signature:

CADTH **DCODR** PAN-CANADIAN ONCOLOGY DRUG REVIEW

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Erin Kennedy

Name of drug and indication under review: Regoratenib for HCC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A. Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? □ Yes D/No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - Advisory role (e. , advisory boards, Program or Operating Funding \square HTA submission advi ce) (e.g., website) Research/educational grants Conference attendance Royalties
 - Gifts

 - Honoraria
 - Other, please specify: C ick here to enter text
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Cikk here & eter text None

- Travel grants
 - Sponsorship of Events



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text. None

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

None

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:	Click here to enter text.	May 3/2017
Name:	Click here to enter text	Erin Kennicht
Signature:	Click here to enter text.	Erm Kennicht Curr Kinnicht
		()
		\bigcup



Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Brandon Meyers

Name of drug and indication under review: Regoratenib for HCC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 Yes
 No

If no, please go to Section B.

2. What form of payment did you receive? Check all that apply.)

Advisory role (e.g., advisory boards, HTA submission advice)

- Conference attendance
- Royalties
- Gifts
- N Honoraria
- Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

 \square

Click here to enter text CEL GENE

CADTH DCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

IA

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

NIA.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Click here to enter text.

Name: Click here to enter text.

Signature: Click here to enter text.



Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Stephen Welch

Name of drug and indication under review: Reforafenib / HCC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 ☑ Yes
 □ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - Advisory role (e.g., advisory boards, HTA submission advice)
 - □ Conference attendance
 - □ Royalties
 - □ Gifts

☐ Travel grants

(e.g., website)

Program or Operating Funding

Research/educational grants

Sponsorship of Events

- 🛛 Honoraria
- Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

 \square

Amgen – Honoraria \$; ESMO 2016 Consultant \$



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: September 22, 2017

Stephen Welch

Name:

hel ien Welch

Signature: